Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX stock is up 2600% this year and the excitment is about to restart. This is a binary bet so the bull vs.

Novavax Stock Stalemate Is About to Catch Fire

Novavax on Tuesday named a team of executives to lead the exploration of a possible Covid-19/flu combo vaccine, for after the pandemic, as it continues late-stage trials on its Covid vaccine. The post Novavax Sets Up Team To Explore A Combination Covid-19/Flu Vaccine Post-Pandemic appeared first on Investor's Business Daily.

Novavax Sets Up Team To Explore A Combination Covid-19/Flu Vaccine Post-Pandemic

AstraZeneca

BioNTech SE

CureVac B.V

GlaxoSmithKline

Johnson & Johnson

Moderna

Pfizer

Sanofi

There's little doubt that COVID-19 vaccines will save many lives, but that doesn't mean investors will be rewarded.

Is the Coronavirus Vaccine Market Oversaturated?

Can Little Novavax Beat Its Big Coronavirus Vaccine Rivals?

There's a lot riding on Novavax's novel coronavirus vaccine candidate, making NVAX stock a biotech lottery ticket for bold traders. The post Novavax Is Incredibly Risky but Worth a Small Allocation appeared first on InvestorPlace.

Novavax Is Incredibly Risky but Worth a Small Allocation

The stock has soared by 2,700% so far this year. Is it still worth investing in today?

Is Novavax Stock Too Risky to Buy Today?

These COVID-19 vaccine leaders offer very different risk-reward propositions.

Better Coronavirus Stock: Johnson & Johnson vs. Novavax

Novavax has used its 15 minutes of fame to great success. But unless its Covid-19 vaccine launches soon, NVAX stock is set to decline.

Covid-19 Therapeutics May Push Novavax Out of the Spotlight

Expect NVAX stock to exceed the $200 mark with two solid growth catalysts in its Covid 19 and Nanoflu vaccine The post Don’t Heed The Bearish Calls and Invest in Novavax appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG America’s #1 Stock Picker Reveals His Next 1,000% Winner Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Could Tiny “Super” Battery Kill Big Tech?

Don’t Heed The Bearish Calls and Invest in Novavax

Vaxart

But are they likely to outperform in the long run?

2 Healthcare Stocks That Could Soar in 2020

Novavax got a manufacturing partner in mid-September to make 2 billion doses. Despite NVAX stock going sideways since then, it remains a buy.

If You’re Placing Bets on Vaccine Winners, Novavax Ought to Be on Your List 

Novavax, Inc. (NASDAQ: NVAX) shares, which peaked at $189.40 in early August, gave back some of their gains through August and early September. The stock bottomed out at $83.22 on Sept.

COVID-19 Vaccine Developer Novavax In Spotlight As Insiders Offload Shares

With Covid-19 penetrating the White House, the value of NVAX stock becomes all the more apparent

The Deep Price Pullback Is Your Signal to Buy Novavax

The vaccine specialist is squarely in the COVID-19 discussion.

Why Is Everyone Talking About Novavax Stock?

The Energy sector was one of the biggest winners on the day, coming after weeks of hard-hit commodity prices finally getting a little traction.

Small-Caps, Energy Win the Trading Day

Inovio Pharmaceuticals

One offers massive potential for gains. The other offers security.

Should You Buy Biotech or Big Pharma in the COVID-19 Vaccine Race?

The value of this vaccine specialist has shifted dramatically because of the coronavirus.

Will Big Pharma Acquire Novavax?

NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its influenza vaccine.

The Real Value in Novavax Goes Beyond the Coronavirus

Innovative Industrial Properties

Got $5,000? 3 Stocks to Buy That Could Double by 2022

The Biggest Coronavirus Vaccine Winner So Far

The announcement of a Phase 3 vaccine trial in the United Kingdom keeps Novavax in contention and shares NVAX stock on investors’ radar. The post Novavax Gains With Start of Phase 3 Vaccine Trial appeared first on InvestorPlace.

Novavax Gains With Start of Phase 3 Vaccine Trial

Big Lots

Co-Diagnostics

Textainer Group Holdings Limited

TTM Technologies

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Top Small Cap Stocks for October 2020

With new competition joining the fray in the Covid-19 vaccine race, NVAX stock looks vulnerable. However, the enormous complexity of this arena gives Novavax a fighting chance.

Deep Diving the Complex Narrative Behind Novavax

Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.

Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax

GAITHERSBURG, Md., Sept.  28, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The presentations are part of the 2020 World Vaccine Congress Washington, taking place virtually September 28-October1, 2020.

News for Novavax Stock (NVAX)